Using Biomarkers to Optimize Antibiotic Strategies in Sepsis

ID: NCT02207114
Status: Active, not recruiting
Phase: N/A
Start Date: January 01, 2012
First Submitted: February 03, 2014
Last Updated: February 05, 2018
Results: N/A
Sponsors & Collaborators: University of Pennsylvania
Location: United States
Conditions: Sepsis
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

Study Description

Brief Summary

The proposed work will provide critical insights into the potential impact of a biomarker-based algorithm on reducing unnecessary antibiotic use in different adult and pediatric/neonatal ICU's. This proposal will also assess the costs (or savings) of a biomarker-based intervention. Overall, the results of this work will be critical in informing future strategies to eliminate unnecessary antibiotic use and curb the continued rise in antimicrobial resistance.

Detailed Description

The goal of this project is reduce unnecessary use of antibiotics in the ICU. The purpose of Phase I of the study is to identify the biomarker, or combination of biomarkers, that provides optimal test characteristics in identifying adults and children/neonates with presumed sepsis who have a very low likelihood of bacterial infection. Results of Phase I will result in development of a biomarker-based algorithm to inform need for antibiotic use in ICU patients. In Phase II, the impact of this biomarker-based algorithm on reducing antibiotic use in the ICU will be determined. Costs or savings associated with the algorithm will also be assessed.
Condition or disease Intervention/treatment Phase

Sepsis

Other: Biomarker Algorithm Intervention
Other Names
N/A

Tracking Information

First Submitted DateFebruary 03, 2014
Last Update Posted DateFebruary 05, 2018
Start DateJanuary 01, 2012
Anticipated Completion DateApril 01, 2018
Primary Completion DateDecember 01, 2016
Results First Submitted DateN/A
Received Results Disposit DateN/A

Current Primary Outcome Measures

  • Duration of antibiotic therapy started upon enrollment for presumed sepsis [Time Frame: Two years]

    The primary outcome is the duration of antibiotic treatment after enrollment, expressed in days. This variable will focus specifically on the antibiotic agents given for the episode of presumed sepsis for which the patient was included in the study.

Original Primary Outcome Measures

Not Available

Current Secondary Outcome Measures

  • Subject's Final Disposition [Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 6 days]

    This includes assessing ICU mortality, hospital mortality, or hospital discharge as an ultimate outcome.

Original Secondary Outcome Measures

Not Available

Study Design

Brief TitleUsing Biomarkers to Optimize Antibiotic Strategies in Sepsis
Official TitleSoutheastern Pennsylvania Adult and Pediatric Prevention Epicenter Network - Randomized Control Trial
Brief Summary

The proposed work will provide critical insights into the potential impact of a biomarker-based algorithm on reducing unnecessary antibiotic use in different adult and pediatric/neonatal ICU's. This proposal will also assess the costs (or savings) of a biomarker-based intervention. Overall, the results of this work will be critical in informing future strategies to eliminate unnecessary antibiotic use and curb the continued rise in antimicrobial resistance.

Detailed Description

The goal of this project is reduce unnecessary use of antibiotics in the ICU. The purpose of Phase I of the study is to identify the biomarker, or combination of biomarkers, that provides optimal test characteristics in identifying adults and children/neonates with presumed sepsis who have a very low likelihood of bacterial infection. Results of Phase I will result in development of a biomarker-based algorithm to inform need for antibiotic use in ICU patients. In Phase II, the impact of this biomarker-based algorithm on reducing antibiotic use in the ICU will be determined. Costs or savings associated with the algorithm will also be assessed.

Study TypeInterventional
Study PhaseN/A
Estimated Enrollment
145
Allocation
Randomized
Interventional Model
Parallel Assignment
Masking
None (Open Label)
Primary Purpose
Diagnostic
Conditions
Sepsis
Target Follow-Up Duration N/A
Biospecimen:
N/A
Sampling MethodN/A
Study PopulationN/A
Intervention
Other: Biomarker Algorithm Intervention

The intervention will consist of using the biomarker identified as useful in Phase I to compile an algorithm along containing the patient's biomarker assay results and providing this as additional information for a clinical team consider using to assist in deciding to continue antibiotics. Biomarker algorithms may be different for adult versus pediatric patients, and across different types of ICUs.

Other Names
Study Groups/Cohorts
Observational
9 blood biomarkers (including C reactive protein and Procalcitonin) will be assessed across 3 days. Results will not be shared with the subject's medical team. At 3 days, the definitive diagnosis of infection will be determined using Center for Disease Control (CDC) criteria; this will serve as the gold standard for determining biomarker test characteristics. Additional data to collect: demographics, comorbidities, medication use (like antibiotics), lab cultures, x-rays, sepsis resolution, length of hospital stay, and ultimate outcome (i.e., discharge, death). Phase I will identify the biomarker(s) providing the greatest negative predictive value in identifying patients at very low likelihood bacterial infection.

Biomarker Algorithm Intervention
The Algorithm arm is equivalent to the intervention. Biomarker algorithm along with the patient's biomarker assay results will be given to clinical team to assist in deciding to continue antibiotics. The intervention will consist of using the biomarker identified as useful in Phase I to compile an algorithm along containing the patient's biomarker assay results and providing this as additional information for a clinical team consider using to assist in deciding to continue antibiotics. Biomarker algorithms may be different for adult versus pediatric patients, and across different types of ICUs.

Study Arms
Experimental Biomarker Algorithm Intervention
The Algorithm arm is equivalent to the intervention. Biomarker algorithm along with the patient's biomarker assay results will be given to clinical team to assist in deciding to continue antibiotics. The intervention will consist of using the biomarker identified as useful in Phase I to compile an algorithm along containing the patient's biomarker assay results and providing this as additional information for a clinical team consider using to assist in deciding to continue antibiotics. Biomarker algorithms may be different for adult versus pediatric patients, and across different types of ICUs.
Other : Biomarker Algorithm Intervention
The intervention will consist of using the biomarker identified as useful in Phase I to compile an algorithm along containing the patient's biomarker assay results and providing this as additional information for a clinical team consider using to assist in deciding to continue antibiotics. Biomarker algorithms may be different for adult versus pediatric patients, and across different types of ICUs.

Arm Intervention/Treatment
Experimental Biomarker Algorithm Intervention
The Algorithm arm is equivalent to the intervention. Biomarker algorithm along with the patient's biomarker assay results will be given to clinical team to assist in deciding to continue antibiotics. The intervention will consist of using the biomarker identified as useful in Phase I to compile an algorithm along containing the patient's biomarker assay results and providing this as additional information for a clinical team consider using to assist in deciding to continue antibiotics. Biomarker algorithms may be different for adult versus pediatric patients, and across different types of ICUs.
Other : Biomarker Algorithm Intervention

Recruitment Information

Recruitment Status:Active, not recruiting
Enrollment145
Completion DateApril 01, 2018
Eligibility Criteria: Inclusion Criteria:
1. SIRS Criteria
SIRS is considered to be present when patients have more than one of the following clinical findings:
- body temperature >38°C or <36°C
- heart rate >90 min-1
- respiratory rate of >20 min-1 or a Paco2 of <32 mm Hg
- and a white blood cell count of >12,000 cells µL-1 or <4,000 µL-1
2. new empiric antibiotic therapy is initiated, indicating the suspicion of infection. Accepted criteria for SIRS will be used for the Medical Intensive Care Unit and Surgical Intensive Care Unit populations, with appropriate age-specific vital signs definitions to help make the definitions relevant for the Pediatric Intensive Care Unit population.

Exclusion Criteria:
1. a code status of "do not resuscitate"
2. absence of initiation or expansion of antibiotic therapy despite meeting criteria for sepsis
3. presence of an immunocompromising condition.
An immunocompromising condition will be defined as one of the following:
- human immunodeficiency virus (HIV) infection with a t-helper cell (CD4) count <200 cell/mm3; 2) immunosuppressive therapy after organ transplantation
- neutropenia (<500 neutrophils/mm3)
- active chemotherapy within the 3 months preceding eligibility or
- diagnosis of cystic fibrosis.
These criteria all represent conditions in which antibiotic use is much less likely to be decreased regardless of the results of a biomarker and are consistent with exclusion criteria used in past studies of the impact of biomarkers.
GenderAll
Age N/A to N/A
Accepts Healthy VolunteersNo
Contacts
Not Available
Listed Location Countries
United States

Administrative Information

NCT Number:NCT02207114
Other Study ID Numbers
813623
Has Data Monitoring CommitteeYes
U.S. FDA-regulated Product Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Device Product Not Approved or Cleared by U.S. FDA: No
IPD Sharing Statement
Not Available
Responsible Party,
Study Sponsor
University of Pennsylvania
Collaborators
Not Available
Investigators
Principal Investigator
Ebbing Lautenbach, MD,MPH,MSCE
Univeristy of Pennsylvania